Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04325594
Other study ID # RCCCT 02-02-2020
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 1, 2020
Est. completion date April 1, 2023

Study information

Verified date April 2023
Source The Research-Clinical Center for Cardiac Surgery and Transplantology LLP
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to optimize the complex treatment of chronic heart failure of non-ischemic etiology by supplementing umbilical cord mesenchymal stem cells to the standard drug therapy.


Description:

The purpose of this study is to optimize the complex treatment of non-ischemic dilated cardiomyopathy by supplementing the standard drug therapy with intracoronary administration of umbilical cord-derived mesenchymal stromal cells. Sixty patients will be selected and randomly divided into the main and control groups in a 1: 1 ratio. Patients of the main group will receive complex treatment based on the addition to the standard drug therapy of intracoronary administration of 10 million mesenchymal stromal cells of the umbilical cord, and patients of the control group will receive only standard drug therapy. Every patient will maintain their standard treatment of chronic heart failure, with maximum tolerated dosage without side effects. The day of infusion will be considered day zero. From that moment, followup will be divided into 0-1,1-3 and 3-6 months. Clinical results will be analyzed after completion of 6 months of followup.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date April 1, 2023
Est. primary completion date January 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women over 18 years of age, who are registered in the dispensary at the The Research-Clinical Center for Cardiac Surgery and Transplantology; - The previously established clinical diagnosis of Dilated cardiomyopathy in the stage III-IV of New York Heart Association classification; - Non-ischemic etiology of Dilated cardiomyopathy according to coronary angiography or computed tomography of the heart with contrast; - Decreased contractile function of the heart the left ventricular ejection fraction =35% according to transthoracic echocardiography and computed tomography of the heart with contrast; - Presence of automatic (implantable) cardiac defibrillator; - Lack of laboratory and clinical data on dysfunctions or insufficiency of other internal organs; - The absence of a history of cancer over the past 5 years and deviations according to the analysis of tumor markers; - Signed voluntary informed consent to participate in the study. Exclusion Criteria: - Coronary artery disease, previously undergone cardiac surgery, including stenting of the coronary arteries; - The presence of clinically significant valve pathology, blood clots in the cavities of the heart, aneurysms of the left ventricle, hypertrophic, early postpartum, alcoholic or restrictive cardiomyopathy, congenital heart defects and resistant hypertension; - A history of stroke in the past 2 years; - A history of autoimmune and immunodeficiency diseases; - Polyvalent allergy; - Decompensation of concomitant chronic diseases; - Reception of systemic corticosteroids, cytostatics, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), as well as drugs that deplete DNA or cytotoxic drugs, the last intake of which was within four weeks before the study; - Hepatitis B and / or C, syphilis, HIV-carriage or AIDS; - The presence of acute systemic infections requiring targeted antibiotic therapy; - A history of untreated peptic ulcer and bleeding from the gastrointestinal tract; - The presence of early transferred closed and open craniocerebral injuries that have a clinical manifestation and require specialized treatment; - A history of uncontrolled epileptic seizures; - Porphyria; - The need for hospitalization and treatment in a hospice; - Alcohol and drug abuse, lack of permanent residence, severe depression, disorientation, distant living.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Cardiac catheterization
Catheterization of the right and left heart cavities
Biological:
Intracoronary administration of the umbilical cord-derived mesenchymal stromal cells
After performing cardiac catheterization, selective coronary angiography will be performed abruptly to assess the condition of the coronary canal by access through the right radial or common femoral artery on the right after 70 U/kg of heparin iv. Then 20 ml of the finished suspension (1×10(7) umbilical cord-derived mesenchymal stromal cells diluted in 20 ml of heparinized saline) will be administrated into the mouth of the left coronary artery (LCA) without occlusion of the vessel with a balloon catheter and without stopping the coronary blood flow. Cell injection will be carried out using a standard 6 Fr catheter for selective coronary angiography with perfusion for 10 minutes at a volume rate of 2 ml/min, thereby introducing 1×10(6) cells per minute

Locations

Country Name City State
Kazakhstan The Research-Clinical Center for Cardiac Surgery and Transplantology LLP Taraz Zhambyl

Sponsors (2)

Lead Sponsor Collaborator
The Research-Clinical Center for Cardiac Surgery and Transplantology LLP State-Financed Health Facility "Samara Regional Medical Center Dinasty"

Country where clinical trial is conducted

Kazakhstan, 

Outcome

Type Measure Description Time frame Safety issue
Primary change in the contractile function of the heart changes in the ejection fraction of the right and left ventricles evaluated by transthoracic echocardiography and computed tomography 1,3,6 months
Primary change in the size of the heart changes in the size of the right and left atrium, end diastolic and end systolic size of the right and left ventricles evaluated by transthoracic echocardiography and computed tomography 1,3,6 months
Primary change in the volumes of the heart changes in the volumes of the right and left atrium, end diastolic and end systolic volumes of the right and left ventricles evaluated by transthoracic echocardiography and computed tomography 1,3,6 months
Secondary change in the clinical condition evaluated by the Scale for Heart failure to Optimize Clinical Status changes in the clinical condition evaluated by the Scale for Heart failure to Optimize Clinical Status (SHOCS). The SHOCS scale consists of 10 points. The maximum possible score is 20, and the minimum is 0. Higher scores indicate a worse or worsening clinical condition, while lower scores or decreasing scores indicate a better clinical condition. 1,3,6 months
Secondary change in the markers of myocardial dysfunction changes in the markers of myocardial dysfunction of the serum level of amino-terminal pro-brain natriuretic peptide 1, 3 and 6 months
Secondary change in the in the 6-minute walk test changes in the 6-minute walk test, defined as the changes in the distance of traveled 1, 3 and 6 months
Secondary change in the functional status change in the functional status according to the New York Heart Association classification 1, 3 and 6 months
Secondary change in the quality of life evaluated by the questionnaire Short Form 12 Healthy Survey change in the quality of life evaluated by the questionnaire Short Form 12 Healthy Survey (SF-12). The SF 12 questionnaire consists of 12 items. The low level of the quality of life corresponds to estimates of 36-47 points, average of 24-35 points, high of 12-23 points. 1, 3 and 6 months
Secondary change in the quality of life evaluated by the Kansas City Cardiomyopathy Questionnaire changes in the quality of life evaluated by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ is composed of 23 items. The options for the answers are of 1 to 5, 6 or 7 points and the score of each of its dimensions has a theoretical range from 0 to 100, 100 being the best outcome. 1, 3 and 6 months
Secondary change in the quality of life evaluated by the Minnesota Living with Heart Failure Questionnaire changes in the quality of life evaluated by the Minnesota Living with Heart Failure (MLHF) Questionnaire. The MLHF questionnaire is composed of 21 items. The maximum possible scores being 105 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life. 1, 3 and 6 months
See also
  Status Clinical Trial Phase
Completed NCT03597646 - The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure N/A
Terminated NCT04065997 - Apogee International
Withdrawn NCT03675113 - Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure N/A
Completed NCT02916160 - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study Phase 4
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Completed NCT02247245 - The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients. N/A
Completed NCT02268500 - VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT) Phase 4
Completed NCT01919918 - Muscle Afferent Feedback Effects in Patients With Heart Failure Phase 1
Terminated NCT01906957 - Cognition and Exercise Training N/A
Not yet recruiting NCT01669395 - Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial N/A
Completed NCT00984529 - Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia N/A
Recruiting NCT00863421 - Sleep Disordered Breathing in Patients With Chronic Heart Failure N/A
Completed NCT02840565 - Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 Phase 1
Completed NCT02441218 - Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study Phase 3
Completed NCT00149409 - Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure Phase 2/Phase 3
Terminated NCT05532046 - A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT) Phase 1
Recruiting NCT04984928 - Readmission Risk of Patients With Heart Failure.
Completed NCT02814097 - A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction Phase 2
Active, not recruiting NCT05560737 - ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
Recruiting NCT03286127 - Palliative Outcome Evaluation Muenster I